Operating

Accretion (Amortization) of Investment Discounts and Premiums

Analysis

StatementCash Flow Statement
SectionOperating
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
Metric ID: schw_accretion_amortization_investment_discounts

Historical Data

2 periods
 Q1 '25Q1 '26
Value$0.00$1.23M
Range$0.00 – $1.23M

Frequently Asked Questions

What is Kailera Therapeutics 's accretion (amortization) of investment discounts and premiums?
Kailera Therapeutics (KLRA) reported accretion (amortization) of investment discounts and premiums of $1.23M in Q1 2026.